These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3382197)

  • 1. [Intensive chemotherapy of refractory anemia with excess of blasts].
    Dohy H; Kyo T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1223-8. PubMed ID: 3382197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of aggressive chemotherapy for myelodysplastic syndromes.
    Dohy H; Kyo T
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
    [No Abstract]   [Full Text] [Related]  

  • 3. [Successful emergency operation for massive hemorrhage due to jejunal angiodysplasia after intensive chemotherapy in a patient with refractory anemia with excess of blasts].
    Morita K; Mizuno T; Itoh R; Suzuki H; Tanaka I
    Rinsho Ketsueki; 1998 Jul; 39(7):526-31. PubMed ID: 9750461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy of adult ANLL].
    Kyo T; Maehama S
    Rinsho Ketsueki; 1989 Aug; 30(8):1157-62. PubMed ID: 2601024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
    Creutzig U; Bender-Götze C; Ritter J; Zimmermann M; Stollmann-Gibbels B; Körholz D; Niemeyer C
    Leukemia; 1998 May; 12(5):652-9. PubMed ID: 9593261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
    Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful induction chemotherapy for childhood RAEB-T with VP-16: a case report].
    Tanizawa A; Sonomura T; Wakazono Y; Akiyama Y; Kubota M; Mikawa H
    Rinsho Ketsueki; 1989 Jul; 30(7):1052-7. PubMed ID: 2810790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
    Moriyama Y; Urushiyama M; Ohnishi M; Koyama S; Hirosawa H; Hanano M; Fuse I; Takai K; Nagayama R; Fujiwara M; Kishi K; Takahashi M; Koike T; Sakai C; Kashimura M; Miura R; Aoyagi A; Sanada M; Hattori A; Shibata A; Shinada S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1549-54. PubMed ID: 6892201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Refractory anemia with excess myeloblast in transformation induced remission by combined oral administration of cytarabine ocfosfate and 6-mercaptopurine].
    Fukumi S; Mizorogi F; Matsuo A; Sato H; Abe T
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):945-8. PubMed ID: 7794001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
    Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients.
    Bruzzese L; Abbadessa A; Ottaiano L; Arcidiacone G
    Haematol Blood Transfus; 1987; 30():315-21. PubMed ID: 3623239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
    Shiga Y; Shichishima T; Aikawa K; Gotoh J; Furukawa T; Yamagiwa A; Ishibashi T; Maruyama Y
    Rinsho Ketsueki; 1994 May; 35(5):501-5. PubMed ID: 8028198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Differentiating effect of the oral administration of vitamin D and vitamin A in acute myelocytic leukemia after BHAC-DMP therapy].
    Yamane T; Furukawa Y; Inoue T; Sagawa H; Yokomatsu Y; Kishida T; Sasaki A; Kojima K; Sannomiya Y; Yoshikawa T
    Rinsho Ketsueki; 1988 May; 29(5):765-8. PubMed ID: 3216506
    [No Abstract]   [Full Text] [Related]  

  • 18. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
    Bennett JM; Young MS; Liesveld JL; Paietta E; Miller KB; Lazarus HM; Marsh RD; Friedenberg WR; Saba HT; Hayes FA; Dewald GW; Hiddemann W; Rowe JM
    Am J Hematol; 2001 Jan; 66(1):23-7. PubMed ID: 11426487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of 58 patients with acute leukemia].
    Sasaki A; Tsukaguchi M
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1303-7. PubMed ID: 1503484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.